Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
Diabetes Care|October 8, 2009
Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4Vito Lampasona, Antonio Petrone, Claudio Tiberti, et al.
Diabetes, Obesity & Metabolism|July 26, 2024
Follow-up and monitoring programme in children identified in early-stage type 1 diabetes during screening in the general population of ItalyValentino Cherubini, Enza Mozzillo, Dario Iafusco, et al.
Biology|December 24, 2021
COVID-19 in Solid Organ Transplant Recipient: Exploring Cumulative Incidence, Seroprevalence and Risk Factors for Disease SeverityRossana Caldara, Paola Maffi, Sabrina Costa, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 31, 2010
Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature reviewSara Madaschi, Alessandro Rossini, Ilaria Formenti, et al.
The Journal of Clinical Investigation|September 29, 2020
COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domainMassimiliano Secchi, Elena Bazzigaluppi, Cristina Brigatti, et al.
Diabetes|May 15, 2015
Detection of Antibodies Directed to the N-Terminal Region of GAD Is Dependent on Assay Format and Contributes to Differences in the Specificity of GAD Autoantibody Assays for Type 1 DiabetesAlistair J K Williams, Vito Lampasona, Michael Schlosser, et al.
Journal of Autoimmunity|March 1, 2006
Monoclonal antibody 76F distinguishes IA-2 from IA-2beta and overlaps an autoantibody epitopeSandra Piquer, Lionel Valera, Vito Lampasona, et al.
The Journal of Clinical Endocrinology and Metabolism|October 31, 2021
No Evidence of Long-Term Disruption of Glycometabolic Control After SARS-CoV-2 InfectionAndrea Laurenzi, Amelia Caretto, Chiara Molinari, et al.
Frontiers in Endocrinology|July 6, 2023
Post hoc analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of respondersValeria Sordi, Paolo Monti, Vito Lampasona, et al.
Clinical and Translational Gastroenterology|October 8, 2020
Autoantibodies Toward ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase Are Reliable Serological Pre-endoscopic Markers of Corpus Atrophic GastritisEdith Lahner, Ilaria Marzinotto, Vito Lampasona, et al.
Pageof 9